abstract |
Disclosed herein are kinase inhibitory compounds, such as receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions and/or combinations can be used to treat or prevent a kinase-associated disease or condition, in particular a RIP1-associated disease or condition. |